Literature DB >> 31838714

Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand?

A Szeliga1, A Podfigurna1, G Bala1, B Meczekalski2.   

Abstract

BACKGROUND: Recent studies have found that kisspeptin/neurokinin B/dynorphin neurons (KNDy neurons) in the infundibular nucleus play a crucial role in the reproductive axis. Analogs, both agonists and antagonists, of kisspeptin and neurokinin B (NKB) are particularly important in explaining the physiological role of KNDy in the reproductive axis in animals. The use of kisspeptin and NKB analogs has helped elucidate the regulators of the hypothalamic reproductive axis.
PURPOSE: This review describes therapeutic uses of Kiss-1 and NKB agonists, most obviously the use of kisspeptin agonists in the treatment for infertility and the induction of ovulation. Kisspeptin antagonists may have potential clinical applications in patients suffering from diseases associated with enhanced LH pulse frequency, such as polycystic ovary syndrome or menopause. The inhibition of pubertal development using Kiss antagonists may be used as a therapeutic option in precocious puberty. Kisspeptin antagonists have been found capable of inhibiting ovulation and have been proposed as novel contraceptives. Hypothalamic amenorrhea and delayed puberty are conditions in which normalization of LH secretion may potentially be achieved by treatment with both kisspeptin and NKB agonists. NKB antagonists are used to treat vasomotor symptoms in postmenopausal women, providing rapid relief of symptoms while supplanting the need for exogenous estrogen exposure.
CONCLUSIONS: There is a wide spectrum of therapeutic uses of Kiss-1 and NKB agonists, including the management of infertility, treatment for PCOS, functional hypothalamic amenorrhea or postmenopausal vasomotor symptoms, as well as contraceptive issues. Nevertheless, further research is needed before kisspeptin and NKB analogs are fully incorporated in clinical practice.

Entities:  

Keywords:  Agonist; Antagonist; KNDy; Kisspeptin; Neurokinin B

Mesh:

Substances:

Year:  2019        PMID: 31838714     DOI: 10.1007/s40618-019-01160-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  52 in total

1.  Evidence from the agonadal juvenile male rhesus monkey (Macaca mulatta) for the view that the action of neurokinin B to trigger gonadotropin-releasing hormone release is upstream from the kisspeptin receptor.

Authors:  Suresh Ramaswamy; Stephanie B Seminara; Tony M Plant
Journal:  Neuroendocrinology       Date:  2011-08-10       Impact factor: 4.914

2.  Role of a neurokinin B receptor antagonist in the regulation of ovarian function in healthy women.

Authors:  Karolina Skorupskaite; Jyothis George; Richard A Anderson
Journal:  Lancet       Date:  2015-02-26       Impact factor: 79.321

3.  Acute and subacute effects of a synthetic kisspeptin analog, C6, on serum concentrations of luteinizing hormone, follicle stimulating hormone, and testosterone in prepubertal bull calves.

Authors:  P A Parker; E A Coffman; K G Pohler; J A Daniel; V Aucagne; M Beltramo; B K Whitlock
Journal:  Theriogenology       Date:  2019-03-06       Impact factor: 2.740

Review 4.  Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.

Authors:  Lise Thomsen; Peter Humaidan
Journal:  Curr Opin Obstet Gynecol       Date:  2015-06       Impact factor: 1.927

Review 5.  Neurokinin B and the hypothalamic regulation of reproduction.

Authors:  Naomi E Rance; Sally J Krajewski; Melinda A Smith; Marina Cholanian; Penny A Dacks
Journal:  Brain Res       Date:  2010-08-25       Impact factor: 3.252

6.  TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction.

Authors:  A Kemal Topaloglu; Frank Reimann; Metin Guclu; Ayse Serap Yalin; L Damla Kotan; Keith M Porter; Ayse Serin; Neslihan O Mungan; Joshua R Cook; Sazi Imamoglu; N Sema Akalin; Bilgin Yuksel; Stephen O'Rahilly; Robert K Semple
Journal:  Nat Genet       Date:  2008-12-11       Impact factor: 38.330

7.  In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Authors:  Lee A Dawson; Christopher J Langmead; Adeshola Dada; Jeannette M Watson; Zining Wu; Raúl de la Flor; Gareth A Jones; Jane E Cluderay; Eric Southam; Graham S Murkitt; Mark D Hill; Declan N C Jones; Ceri H Davies; Jim J Hagan; Paul W Smith
Journal:  Eur J Pharmacol       Date:  2009-10-30       Impact factor: 4.432

8.  Interactions between kisspeptins and neurokinin B.

Authors:  Víctor M Navarro
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications.

Authors:  Jacques Young; Jyothis T George; Javier A Tello; Bruno Francou; Jerome Bouligand; Anne Guiochon-Mantel; Sylvie Brailly-Tabard; Richard A Anderson; Robert P Millar
Journal:  Neuroendocrinology       Date:  2012-02-24       Impact factor: 4.914

10.  Kisspeptin receptor agonist (FTM080) increased plasma concentrations of luteinizing hormone in anestrous ewes.

Authors:  Brian K Whitlock; Joseph A Daniel; Lisa L Amelse; Valeria M Tanco; Kelly A Chameroy; F Neal Schrick
Journal:  PeerJ       Date:  2015-11-05       Impact factor: 2.984

View more
  2 in total

1.  Kisspeptin-8 Induces Anxiety-Like Behavior and Hypolocomotion by Activating the HPA Axis and Increasing GABA Release in the Nucleus Accumbens in Rats.

Authors:  Katalin Eszter Ibos; Éva Bodnár; Zsolt Bagosi; Zsolt Bozsó; Gábor Tóth; Gyula Szabó; Krisztina Csabafi
Journal:  Biomedicines       Date:  2021-01-25

Review 2.  Neuroendocrine Determinants of Polycystic Ovary Syndrome.

Authors:  Anna Szeliga; Ewa Rudnicka; Marzena Maciejewska-Jeske; Marek Kucharski; Anna Kostrzak; Marta Hajbos; Olga Niwczyk; Roman Smolarczyk; Blazej Meczekalski
Journal:  Int J Environ Res Public Health       Date:  2022-03-06       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.